These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22511902)

  • 1. Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.
    Kim YJ; Jang BK; Kim ES; Park KS; Cho KB; Chung WJ; Hwang JS
    Korean J Hepatol; 2012 Mar; 18(1):41-7. PubMed ID: 22511902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.
    Dogan UB; Akin MS; Yalaki S
    World J Gastroenterol; 2013 Dec; 19(46):8678-86. PubMed ID: 24379586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?
    Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen TM; Chen CH; Changchien CS
    J Gastroenterol Hepatol; 2002 Dec; 17(12):1307-11. PubMed ID: 12423276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.
    Yu JW; Sun LJ; Kang P; Yan BZ; Zhao YH
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):185-92. PubMed ID: 22484588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
    Christensen PB; Krarup HB; Laursen AL; Madsen PH; Pedersen C; Schlichting P; Orholm M; Ring-Larsen H; Bukh J; Krogsgaard K
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.
    Al-Ali J; Siddique I; Varghese R; Hasan F
    Ann Hepatol; 2012; 11(2):186-93. PubMed ID: 22345335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
    Pellicelli AM; Romano M; Stroffolini T; Mazzoni E; Mecenate F; Monarca R; Picardi A; Bonaventura ME; Mastropietro C; Vignally P; Andreoli A; Marignani M; D'Ambrosio C; Miglioresi L; Nosotti L; Mitidieri O; Gentilucci UV; Puoti C; Barbaro G; Barlattani A; Furlan C; Barbarini G;
    BMC Gastroenterol; 2012 Nov; 12():162. PubMed ID: 23157720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
    Yu JW; Sun LJ; Kang P; Zhao YH; Yan BZ; Zhu PF
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1002-7. PubMed ID: 22333166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
    Kim KH; Jang BK; Chung WJ; Hwang JS; Kweon YO; Tak WY; Lee HJ; Lee CH; Suh JI
    Korean J Hepatol; 2011 Sep; 17(3):220-5. PubMed ID: 22102389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response.
    Tseng CW; Chen CY; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Lee CC; Wu SF; Tseng KC
    PLoS One; 2014; 9(6):e100207. PubMed ID: 24937007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.